The most common tumors harboring EGFR amplification were colorectal cancer (16.3% [458 of 2,807]), followed by NSCLC (9.0% [1,096 of 12,197]), genitourinary cancers (8.1% [170 of 2,104]), cutaneous tumors (7.4% [45 of 610]), and breast cancer (7.3% [328 of 4,518]; Fig 1A). This evidence concerns the gene EGFR and breast carcinoma.